BK virus associated meningoencephalitis in an AIDS patient treated with HAART
© Vidal et al; licensee BioMed Central Ltd. 2007
Received: 23 April 2007
Accepted: 08 June 2007
Published: 08 June 2007
A severely immune-suppressed AIDS patient was suspected of suffering from BK virus (BKV) meningoencephalitis, after being studied for common causes of neurological complications of co-infectious origin. Polymerase chain reaction (PCR) and sequence analysis of cerebrospinal fluid and brain samples, confirmed the presence of BKV. His clinical condition improved along with the regression of brain lesions, after modifications on his antiretroviral regime. Five months after discharge, the patient was readmitted because of frequent headaches, and a marked inflammatory reaction was evidenced by a new magnetic resonance imaging (MRI). The symptoms paralleled a rising CD4+ lymphocyte count, and immune reconstitution syndrome was suspected. This is the first non-postmortem report of BKV meningoencephalitis in an AIDS patient, showing clinical and radiographic improvement solely under HAART.
Neurological complications associated with HIV-1/AIDS are being recognized with a high frequency that parallels the increased number of AIDS cases . Since the introduction of HAART, morbidity and mortality secondary to primary and secondary neurological opportunistic diseases in HIV-1/AIDS patients have significantly decreased [2, 3]. However, neurocognitive impairments continue to occur in high frequencies, even in countries, with a free and universal access program to HAART, such as Brazil .
Recently, atypical presentations of brain diseases, such as JC virus granule cell neuronopathy, and those related to the reconstitution of the immune system after initiation of HAART have been reported in a growing basis [5–7]. These unusual neurological pictures in AIDS patients represent new diagnostic and therapeutic challenges [7, 8].
BKV meningoencephalitis is a rare polyomaviral infection with fatal outcome when associated with AIDS [9–11]. The clinical picture is devastating, resulting in death from multi-organ failure . Here, we describe the clinical course of an AIDS patient with presumed BKV meningoencephalitis who showed substantial improvement after modification of his HAART regime.
In April 2004, a 43-year-old HIV-1 positive heterosexual male was admitted to the hospital complaining of bilateral headache of moderate intensity accompanied by speech, gait and memory disturbances. HIV-1 infection was diagnosed in July 2003 after an episode of cryptococcal meningitis; with a documented CD4+ lymphocyte count of 6 cells/mm3. His past medical history includes an episode of pancreatitis secondary to lopinavir/ritonavir (July, 2003), and an episode of tuberculous meningitis (October, 2003). On admission, antiretroviral medications included zidovudine, lamivudine, and efavirenz (antiretroviral scheme modified after pancreatitis in August, 2003). Other medications included: fluconazole, TMP-SMX, isoniazid, ofloxacin, ethambutol, and pyrazinamide (rifampin was discontinued and replaced by ethambutol and ofloxacin after a marked increased of hepatic enzymes in November, 2003)
Initial examination revealed mental confusion, dysarthria and ataxia. Baseline cranial CT scan showed two hypodense lesions with mass effect and no contrast enhancement in the left temporo-parietal and right occipito-parietal areas. His CD4+ lymphocyte count was 37 cells/mm3, with an undetectable viral load. Presumptive cerebral toxoplasmosis was diagnosed, and a treatment with sulphadiazine-pyrimetamine, folinic acid, and dexamethasone was started. After 14 days of therapy, the patient's neurological status and CT scan findings remained unchanged. Analysis of the cerebrospinal fluid (CSF) obtained on day 14 after admission showed 12 leukocytes/mm3 (79% lymphocytes, 10% monocytes), glucose of 46 mg/dl and a protein level of 146 mg/dl. Herpes simplex encephalitis was suspected, and acyclovir replaced the medications for toxoplasmosis. After a week on this therapeutic regime, the patient's neurological status remained unaltered, and PCR analysis of CSF was performed, resulting negative for all human herpes viruses, JCV, and for Toxoplasma gondii. Nevertheless, PCR for polyomavirus BKV resulted positive.
Five months after discharge, the patient complained of mild headaches. A new MRI reported improvement of the two lesions previously seen; however, new areas of increased signal intensity of the white matter appeared (Figure 1B). Based on a rising CD4+ lymphocyte count of 144 cells/mm3, and in the absence of any other co-infectious agent, "encephalopathy of unknown origin" secondary to immune reconstitution was suspected. We kept close follow-up without any other intervention, and the patient gradually recovered.
Seven months after discharge, MRI lesions and CD4+ lymphocyte count further improved (Figure 1C.). Since then, and until May 2007, the patient has been in the same HAART regime, with no neurological complaints; his renal and liver function have always been unaltered, and his last CD4 + lymphocyte count was of 336 cells/mm3 with a viral load bellow 400 copies/ml.
Serum Hiv-1 viral load detection
All quantifications of viral load were performed by real-time RT-PCR. The threshold of detection was 400 copies/ml.
BKV and JCV DNA amplification from CSF samples
PCR technique as described by Arthur et. al., was used to amplify the T-antigen gene (173 bp) of both, BKV and JCV. To establish whether BK viral sequences inhibited the reaction, 10 μl of CSF sample were added to duplicate tubes containing the PCR mixture and polyomavirus cloned DNA. An amplification band of 173 bp was analyzed by 2% agarose gel electrophoresis and visualized by exposure to UV light after staining with ethidium bromide. Discriminating between JCV and BKV was performed by treatment of PCR products (10 μl) with the restriction enzyme BamH1 (Invitrogen) and analyzed by electrophoresis on a 3% agarose gel.
BKV and JCV DNA amplification from brain biopsy
DNA was isolated twice from 25 mg of paraffin-embedded tissue using the DNeasy Tissue Kit (QIAGEN, USA). Negative control of extraction was carried out, using water instead of lysed tissue sample. DNA amplification was carried out by seminested-PCR on different amount of DNA purified from paraffin-embedded biopsies. A 150 base pair fragment of the BKV LT-coding region was amplified using the outer primers Pep1 and Pep2 and the inner primers Pep1 and BKS (nt 4513–4529, Dunlop strain). Parameters for the 30 cycles of outer PCR were 95°C denaturation, 54°C annealing and 72°C elongation for 30 sec each, whereas for the inner PCR the annealing temperature was 52°C. Urine from a patient with "polyomavirus associated nephropathy" was used as positive control, while water as negative control. Amplification of the LT region of JCV DNA was carried out by nested-PCR on different amount of DNA, by using set of primers JC1 and JC2 (outer), Pep1 and Pep 2 (inner). Moreover, to discard contamination by other polyomavirus, we performed a western blot analysis with the antibody against JCV/SV40 Tag (94 kDa) and against actin (40 kDa) as a control. Our patient's sample came out negative for the former (data not shown).
PCR products were added to a mixture containing 4 μl of Ready Reaction Premix 2.5X, 2 μl of BigDye Sequencing Applied Biosystems 5X buffer, 3.2 pmol of either forward or reverse primers, and water up to a final volume of 20 μl. The cycle sequencing was performed using the GeneAmp PCR System 9700, with the following protocol: initial denaturation at 96°C for 1', then 25 cycles with a first step at 96°C for 10", a second step at 50°C for 5" and the last rapid thermal ramp to 60°C for 4'. 5 μl of the purified product underwent electrophoresis on an ABI PRISM 310 Genetic Analyzer. Sequence homology searches were performed using BLAST at NCBI (USA).
We report the first in-vivo case of BKV-associated meningoencephalitis in an AIDS patient who showed clinical improvement and regression of brain lesions while on HAART.
BKV infection is generally a benign condition in immunocompetent patients, and the causative agent of "polyomavirus associated nephropathy" and hemorrhagic cystitis in immunocompromised individuals [12, 14]. However, there is a growing body of evidence demonstrating its neurotropism [14–16]. Among AIDS patients, only 3 cases of BKV- meningoencephalitis have been described, and all of them reported post-mortem [9–12].
Initially, the morphology of the lesions and the cytochemical profile of the CSF samples led us to empirically diagnose the patient with cerebral toxoplasmosis and herpes simplex encephalitis afterwards. However, the lack of response to treatment and the presence of BKV DNA in CSF samples and brain tissue led us to reclassify the patient as with BKV meningoencephalitis.
Compared to the other 3 cases reported, the presence of BKV DNA in the CSF is a common denominator of true neurological disease. As previously described, the detection of BKV genome in brain samples is unspecific, as it is normally present in 3%–6% of HIV-1 infected patient, even without neurological symptoms . Our patient's histopathological description is identical to the ones previously reported, showing diffuse areas of increased signal [9, 11]. Progressive multifocal leukoencephalopathy was ruled out because of the normal morphology of oligodendrocytes. In terms of the radiological changes, our case is similar to the previous ones, showing areas of increased signal intensity of the periventricular white matter (MRI) . Other descriptions include increased meningeal contrast enhancement along with increased meningeal thickness (MRI) , and marked internal hydrocephalus and periventricular lucencies (CT scan) . None of the previous reports showed features suggesting immune reconstitution inflammatory syndrome (IRIS).
Our main limitation to conclude that BKV is the causative agent of the neurological disorders is the lack of demonstration of the virus in the brain tissue sample, either by immunohistochemistry or by in-situ hybridization. Tissue samples extracted by stereotactic surgery are limited, and most of the times insufficient to run all diagnostic tests. These limitations were not faced in other reported cases, as all of these were done post-mortem.
Another important difference is the lack of renal/systemic involvement in our patient, when compared to the other cases previously reported. Our patient' renal work up included serial urianalysis and renal function tests that remained normal throughout the course of the disease (creatinine 0.8 mg/dl, BUN of 16 mg/dl, in April, 2004, creatinine of 0.9 mg/dl, BUN of 28 mg/dl in October, 2004,). As an outpatient his renal function has continued in the normal ranges (creatinine of 0.9 mg/dl, BUN of 40 mg/dl, May 2007). The containment of the disease was possibly related to a partial effect of HAART, similar to what has been reported for other AIDS-associated neurological complications in the post-HAART era, opening a broader spectrum of AIDS-associated neurocognitive disorders .
In this case, the change of atazanavir-ritonavir for efavirenz might have helped to reactivate the immune system, improving the symptoms and morphology of the lesions associated with BKV meningoencephalitis. The rationale of this change was based upon our previous experience and the results of an unpublished work describing the benefits of protease inhibitors in the restoration of the CD4 count when compared to non-nucleoside analogs (Riddler SA, Haubrich R, DiRienzo G, et al. A prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection: ACTG 5142. Program and abstracts of the XVI International AIDS Conference; August 13–18, 2006; Toronto, Canada. Abstract THLB0204). Unfortunately, the restoration of the immune system is not innocuous, and as previously described, deleterious effects are found in the context of polyomavirus infection, introduction of HAART, and a rising CD4+ count . Immune reconstitution inflammatory syndrome (IRIS), as the latter phenomenon is known, affects 15% to 45% of patients receiving HAART. CNS involvement hás been reported to occur in the presence of tuberculosis (33%), cryptococcosis (4.2%–15.9%), JC vírus (unknown frequency); being manifested radiologically as the extension or worsening of a previous condition or by the apparison of lesions that are enhanced by contrast, with or without involvement of the meninges and sometimes accompanied by hydrocephalus . In our patient, the newly developed cerebral lesions and the headaches spontaneously resolved.
In conclusion, our report demonstrates that BKV might be the causative agent of meningoencephalitis in AIDS patients, and that this virus must be investigated in higher frequencies in HIV-1 positive patients with neurological manifestations now that its neurotropism has been better documented. In our patient, a previously reported life-threatening and disseminated disease progressed to a mild and focalized neurological condition in the presence of HAART.
José E. Vidal is supported by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) grant 001/0700/000186/2003. Pasquale Ferrante is supported by NIH grant MH068360-01. The authors thank to A.F. Tateno, M.C.A. Bernal, and J.E. Martins for their technical support. We are indebted to Drs. Walter Royal III and Anthony Amoroso, as well as to Elaine B Trujillo for helpful reviews of the manuscript.
- Trujillo JR, Jaramillo-Rangel G, Ortega-Martinez M, Penalva de Oliveira AC, Vidal JE, Bryant J, Gallo RC: International NeuroAIDS: prospects of HIV-1 associated neurological complications. Cell Res. 2005, 15 (11-12): 962-969. 10.1038/sj.cr.7290374View ArticlePubMedGoogle Scholar
- Sacktor N: The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol. 2002, 8 Suppl 2: 115-121. 10.1080/13550280290101094View ArticlePubMedGoogle Scholar
- d'Arminio Monforte A, Cinque P, Mocroft A, Goebel FD, Antunes F, Katlama C, Justesen US, Vella S, Kirk O, Lundgren J: Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol. 2004, 55 (3): 320-328. 10.1002/ana.10827View ArticlePubMedGoogle Scholar
- Oliveira JF, Greco DB, Oliveira GC, Christo PP, Guimaraes MD, Oliveira RC: Neurological disease in HIV-infected patients in the era of highly active antiretroviral treatment: a Brazilian experience. Rev Soc Bras Med Trop. 2006, 39 (2): 146-151. 10.1590/S0037-86822006000200002View ArticlePubMedGoogle Scholar
- Koralnik IJ, Wuthrich C, Dang X, Rottnek M, Gurtman A, Simpson D, Morgello S: JC virus granule cell neuronopathy: A novel clinical syndrome distinct from progressive multifocal leukoencephalopathy. Ann Neurol. 2005, 57 (4): 576-580. 10.1002/ana.20431View ArticlePubMedGoogle Scholar
- Riedel DJ, Pardo CA, McArthur J, Nath A: Therapy Insight: CNS manifestations of HIV-associated immune reconstitution inflammatory syndrome. Nat Clin Pract Neurol. 2006, 2 (10): 557-565. 10.1038/ncpneuro0303View ArticlePubMedGoogle Scholar
- Vendrely A, Bienvenu B, Gasnault J, Thiebault JB, Salmon D, Gray F: Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy. Acta Neuropathol (Berl). 2005, 109 (4): 449-455. 10.1007/s00401-005-0983-yView ArticleGoogle Scholar
- Gray F, Chretien F, Vallat-Decouvelaere AV, Scaravilli F: The changing pattern of HIV neuropathology in the HAART era. J Neuropathol Exp Neurol. 2003, 62 (5): 429-440.PubMedGoogle Scholar
- Bratt G, Hammarin AL, Grandien M, Hedquist BG, Nennesmo I, Sundelin B, Seregard S: BK virus as the cause of meningoencephalitis, retinitis and nephritis in a patient with AIDS. Aids. 1999, 13 (9): 1071-1075. 10.1097/00002030-199906180-00010View ArticlePubMedGoogle Scholar
- Vallbracht A, Lohler J, Gossmann J, Gluck T, Petersen D, Gerth HJ, Gencic M, Dorries K: Disseminated BK type polyomavirus infection in an AIDS patient associated with central nervous system disease. Am J Pathol. 1993, 143 (1): 29-39.PubMed CentralPubMedGoogle Scholar
- Lesprit P, Chaline-Lehmann D, Authier FJ, Ponnelle T, Gray F, Levy Y: BK virus encephalitis in a patient with AIDS and lymphoma. Aids. 2001, 15 (9): 1196-1199. 10.1097/00002030-200106150-00026View ArticlePubMedGoogle Scholar
- Hirsch HH, Steiger J: Polyomavirus BK. Lancet Infect Dis. 2003, 3 (10): 611-623. 10.1016/S1473-3099(03)00770-9View ArticlePubMedGoogle Scholar
- Arthur RR, Dagostin S, Shah KV: Detection of BK virus and JC virus in urine and brain tissue by the polymerase chain reaction. J Clin Microbiol. 1989, 27 (6): 1174-1179.PubMed CentralPubMedGoogle Scholar
- Behzad-Behbahani A, Klapper PE, Vallely PJ, Cleator GM: BK virus DNA in CSF of immunocompetent and immunocompromised patients. Arch Dis Child. 2003, 88 (2): 174-175. 10.1136/adc.88.2.174PubMed CentralView ArticlePubMedGoogle Scholar
- Behzad-Behbahani A, Klapper PE, Vallely PJ, Cleator GM, Bonington A: BKV-DNA and JCV-DNA in CSF of patients with suspected meningitis or encephalitis. Infection. 2003, 31 (6): 374-378.PubMedGoogle Scholar
- Hirsch HH: BK virus: opportunity makes a pathogen. Clin Infect Dis. 2005, 41 (3): 354-360. 10.1086/431488View ArticlePubMedGoogle Scholar
- Vago L, Cinque P, Sala E, Nebuloni M, Caldarelli R, Racca S, Ferrante P, Trabottoni G, Costanzi G: JCV-DNA and BKV-DNA in the CNS tissue and CSF of AIDS patients and normal subjects. Study of 41 cases and review of the literature. J Acquir Immune Defic Syndr Hum Retrovirol. 1996, 12 (2): 139-146.View ArticlePubMedGoogle Scholar
- McArthur JC, Haughey N, Gartner S, Conant K, Pardo C, Nath A, Sacktor N: Human immunodeficiency virus-associated dementia: an evolving disease. J Neurovirol. 2003, 9 (2): 205-221.View ArticlePubMedGoogle Scholar
- Cinque P, Bossolasco S, Brambilla AM, Boschini A, Mussini C, Pierotti C, Campi A, Casari S, Bertelli D, Mena M, Lazzarin A: The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: study of 43 cases with review of the literature. J Neurovirol. 2003, 9 Suppl 1: 73-80.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.